Key facts
- This page summarizes David Arkowitz's Form 4 filing for YUMANITY THERAPEUTICS, INC. (KANT).
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2021, 16:05.
David Arkowitz - 02 Jun 2021 Form 4 Insider Report for YUMANITY THERAPEUTICS, INC. (KANT)
- Form type
- 4
- Accepted by SEC
- 04 Jun 2021, 16:05:34 UTC
- Previous filing
- 01 Jun 2021
- Next filing
- 07 Jun 2021
- SEC filing
- View on sec.gov
- Reporting owner signature
- /s/ Marie Epstein, Attorney-in-Fact
Source evidence
5 source fields
Reporting owner
1 detail
Key filing fact
David Arkowitz filed Form 4 for YUMANITY THERAPEUTICS, INC. (KANT) on 04 Jun 2021.
Change
- Previous filing in this sequence was filed on 01 Jun 2021.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
See Original Filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
KA
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +14,800
- Change %
- Price
- $0.000000
- Shares after
- 14,800
- Date
- 02 Jun 2021
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 14,800
- Exercise price
- $15.26
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares subject to the option shall vest in equal quarterly installments over three years following June 2, 2021.